Features
Spectrum Medical Imaging Co. delivers trusted medical imaging services and supplies, including the GUERBET ELUCIREM 10ML VIAL 10/BX, an advanced gadolinium-based contrast agent. Ideal for hospitals, outpatient centers, and radiology clinics, it supports diagnostic imaging by enhancing clarity in magnetic resonance imaging.
This high-performance agent enables healthcare providers to capture detailed images efficiently. As your reliable contrast media supplier, we’re committed to supporting workflow, accuracy, and exceptional patient care.
ELUCIREM (Gadopiclenol) is a high-relaxivity gadolinium contrast agent used in magnetic resonance imaging (MRI) for adult and pediatric patients aged 2 and older. It plays a vital role in visualizing lesions with abnormal vascularity across a range of full-body imaging applications.
Designed for seamless integration into routine workflows, this contrast media in radiology supports efficient, high-quality diagnostic imaging.
The GUERBET ELUCIREM 10ML VIAL 10/BX delivers the performance and flexibility imaging teams need while reinforcing Spectrum Medical Imaging Co.’s commitment to high-quality medical imaging services and patient care.
The clinical performance of Gadopiclenol is central to its value in diagnostic imaging. It is designed to support healthcare providers in making informed decisions based on clear and detailed MRI images.
ELUCIREM supports the detailed enhancement of abnormal tissues and vascular lesions. This reliable visualization is crucial for accurately identifying and characterizing pathology, ultimately improving diagnostic outcomes and guiding appropriate patient management strategies for healthcare professionals. Clinical studies have demonstrated Concordance in lesion detectability with ELUCIREM.
Patient safety is a primary concern in medical imaging. ELUCIREM features a macrocyclic structure, which is associated with a low retention rate of gadolinium in the human body. Its indication for use in pediatric patients aged 2 years and older, along with consideration for patients at risk, highlights its safety profile.
While Injection site reactions are possible with intravenous injection, the overall safety profile supports its use in various patient populations. Healthcare providers should consider the potential risk associated with gadolinium-containing contrast agents and review patient history, including renal function through laboratory testing, before intravenous administration.
At Spectrum Medical Imaging Co., we simplify access to essential contrast agents like GUERBET ELUCIREM 10ML VIAL 10/BX. Backed by 40 years of industry experience, we address procurement challenges through reliable service, competitive pricing, and end-to-end support for your medical imaging services.
By partnering with Spectrum Medical Imaging Co., you gain more than just a supplier—you gain a reliable resource committed to supporting your operations, improving workflow, and enhancing patient care through trusted diagnostic imaging solutions.
Ensure your imaging department is equipped with reliable contrast solutions. As a leading contrast media supplier, Spectrum Medical Imaging Co. provides fast, dependable access to GUERBET ELUCIREM 10ML VIAL 10/BX, along with full-service support, including contrast injector repair and maintenance. Contact us online to request a quote, check availability, or speak with a product specialist today.
GUERBET ELUCIREM 10ML VIAL 10/BX is a high-relaxivity gadolinium-based contrast agent administered via intravenous injection to enhance visualization during magnetic resonance imaging (MRI). It improves the clarity of diagnostic imaging, particularly for detecting representative lesions in the human body, including the CNS and musculoskeletal systems. ELUCIREM helps healthcare professionals improve concordance in lesion detectability, contributing to more confident clinical decisions during each imaging exam.
As with all gadolinium-containing contrast agents, ELUCIREM should be administered by a trained healthcare provider who can assess patients at risk, including those with renal impairment or a history of allergic reactions. Injection site reactions, mild nausea, or headache may occur. Though rare, the potential risk of more serious reactions should be considered. Clinical studies and laboratory testing support ELUCIREM’s favorable safety profile among gadolinium-based contrast media, making it a reliable option for most patients under appropriate clinical guidance.
ELUCIREM is specifically formulated for use in magnetic resonance imaging and is not used in nuclear medicine or CT imaging. It is a gadolinium contrast agent approved solely for intravenous administration in MRI procedures. For other modalities, alternative contrast solutions may be recommended. Healthcare professionals should select contrast agents based on the imaging modality and the diagnostic goals of the medical imaging procedure.
